PHAT
NASDAQ
$10.65
Phathom Pharmaceuticals Inc (PHAT)
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $23.70 (+122.54%)
Market Cap
$878M
Free Cash Flow Yield
-11.14%
Beta (5Y)
1.26
Price Chart
Valuation
Market Cap$878M
P/S4.30
P/B25.37
Profitability
Total Revenue (TTM)$205M
Gross Profit (TTM)$174M
EBITDA-$96M
Profit Margin-52.1%
Operating Margin-26.5%
EPS-$2.18
Financial Health
Debt-to-Equity-48.6%
Free Cash Flow Yield-11.14%
Growth & Risk
EPS 5Y CAGR-24.73%
Beta (5Y)1.26
Sharpe Ratio0.65